We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Molecular Probe Lights up Proteases in Tumors

By HospiMedica staff writers
Posted on 20 Sep 2007
Scientists have developed a molecular probe that sets aglow tumor cells within living animals. More...
This could ultimately be used to improve diagnosis and treatment of cancer and other diseases.

The probe's main ingredient is a molecule that labels active proteases--protein-destroying enzymes--that run amok in cancerous cells. The molecule is normally invisible to the naked eye but it carries a fluorescent tag that lights up when it binds to the protease. The tag beams out near-infrared light that passes through skin and is detectable with a special camera. The use of the technique in mice was described in a study published in the September 9, 2007, online issue of the journal Nature Chemical Biology.

"Nowadays, the detection of cancer, breast cancer for instance, is normally done by mammography, using X-rays--which might actually increase your risk of cancer. We think these probes may ultimately provide a less harmful, noninvasive method of detecting cancer,” said Galia Blum, Ph.D., a postdoctoral scholar in the laboratory of Matthew Bogyo, Ph.D., assistant professor of pathology at the Stanford University School of Medicine (Stanford, CA, USA).

"The next generation of our experiments will apply the probes during surgery,” said Prof. Bogyo, the study's senior author. "It would be nice to ‘paint' it on tissues so you could distinguish between tumor and non-tumor.”

Professor Bogyo, Dr. Blum, and colleagues designed the probe to bind to a subset of a family of proteases called cysteine cathepsins, which are more active in several types of cancer as well as other diseases. Now they are altering the probe's configuration in an effort to create a variant that recognizes the enzymes involved in apoptosis, the process of cell death. This could eventually allow researchers and doctors to visualize response to chemotherapy in tumors.


Related Links:
Stanford University School of Medicine

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Infant Incubator
OKM 801
Medical Monitor
VITALMAX 4100SL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.